Angitia
- Employees
- 11–50
- Business Model
- B2B
- Total Funding
- $336.0M
- Last Round
- $130.0M Series DFeb 2026
- Rounds
- 5
About
Clinical-stage biotechnology company developing bispecific therapeutics for bone diseases with significant unmet medical needs.
Summary
Angitia is a Biotech company. It has raised $336.0M in total across 5 rounds, most recently a $130.0M Series D round in Feb 2026. Investors include Bain Capital Life Sciences, Frazier Life Sciences and Venrock.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...